AU6357199A - Treatment of gastric asthma - Google Patents

Treatment of gastric asthma

Info

Publication number
AU6357199A
AU6357199A AU63571/99A AU6357199A AU6357199A AU 6357199 A AU6357199 A AU 6357199A AU 63571/99 A AU63571/99 A AU 63571/99A AU 6357199 A AU6357199 A AU 6357199A AU 6357199 A AU6357199 A AU 6357199A
Authority
AU
Australia
Prior art keywords
treatment
gastric asthma
asthma
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU63571/99A
Inventor
David John Lengel
William Leroy Rumsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AU6357199A publication Critical patent/AU6357199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU63571/99A 1998-10-30 1999-10-26 Treatment of gastric asthma Abandoned AU6357199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10635498P 1998-10-30 1998-10-30
US60106354 1998-10-30
PCT/GB1999/003536 WO2000025766A2 (en) 1998-10-30 1999-10-26 Use of nk antagonist for treating gastric asthma

Publications (1)

Publication Number Publication Date
AU6357199A true AU6357199A (en) 2000-05-22

Family

ID=22310952

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63571/99A Abandoned AU6357199A (en) 1998-10-30 1999-10-26 Treatment of gastric asthma

Country Status (3)

Country Link
AU (1) AU6357199A (en)
GB (1) GB9924141D0 (en)
WO (1) WO2000025766A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
CA2432543A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
SE0103668D0 (en) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive leaves
SE0103795D0 (en) * 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of overactive bladder
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (en) 2005-09-29 2007-12-19 Astrazeneca Ab COMPOUNDS DERIVED FROM AZETIDINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9601697D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
US5697112A (en) * 1996-11-08 1997-12-16 Glaxo Wellcome Inc. Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications

Also Published As

Publication number Publication date
GB9924141D0 (en) 1999-12-15
WO2000025766A3 (en) 2000-09-21
WO2000025766A2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
AU2882299A (en) Anti-asthma therapy
AU7772794A (en) Treatment of obesity
AU5289698A (en) Gas treatment devices
AU1772399A (en) Well treatment
ZA979731B (en) Treatment of asthma.
AU2740899A (en) Treatment of liquids
AU1356201A (en) Treatment of hyperproliferative disorders
AU3065999A (en) Compositions and methods for treatment of asthma
AU6357199A (en) Treatment of gastric asthma
AU1289300A (en) Diagnosis of gastric and lung disorders
AU7750100A (en) Method for the treatment of obesity
AU8451298A (en) Treatment of fabrics
AU6366100A (en) Novel methods and reagents for the treatment of osteoarthritis
AU1940800A (en) Combination therapy for the treatment of sepsis
AU2619199A (en) Treatment of waxes
AU4598400A (en) Method of treatment
AU3817899A (en) Therapy of atherosclerosis
AU2382601A (en) Novel method of treatment
AU6112299A (en) Treatment of effluents
AUPQ373899A0 (en) Treatment of asthma II
AU8557598A (en) Treatment of fluids
AUPQ361499A0 (en) Treatment of asthma
AU5524399A (en) Inorgasmia treatment
EP1158991A4 (en) Treatment of asthma
AUPO108596A0 (en) Treatment of obesity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase